Previous studies showed BRAF inhibitors (e.g. vemurafenib and dabrafenib) and MEK inhibitors (e.g. trametinib and cobimetinib) have been shown to be efficient in providing rapid tumor response, prolonging progression-free survival, and bettering OS in BRAF V600-mutated melanoma [54]. The gene discussed is BRAF; the disease is melanoma.